Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Psyence Group Inc C.PSYG

Alternate Symbol(s):  PSYGF

Healthcare Biotechnology Drug Manufacturers - Major
Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its... see more

Recent & Breaking News (CSE:PSYG)

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

GlobeNewswire October 31, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire October 25, 2024

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

GlobeNewswire October 14, 2024

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

GlobeNewswire September 20, 2024

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

GlobeNewswire September 19, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire September 18, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire September 16, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire July 26, 2024

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire April 16, 2024

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

GlobeNewswire March 26, 2024

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study  

GlobeNewswire March 12, 2024

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

GlobeNewswire March 11, 2024

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

GlobeNewswire January 25, 2024

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

GlobeNewswire January 16, 2024

Psyence Group Announces Resignation of Board Member

GlobeNewswire November 20, 2023

Canadian Investment Regulatory Organization Trade Resumption - PSYG

Canada NewsWire November 15, 2023

Canadian Investment Regulatory Organization Trading Halt - PSYG

Canada NewsWire November 15, 2023

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

GlobeNewswire November 15, 2023

Psyence Production Expands Capability

GlobeNewswire October 30, 2023

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

GlobeNewswire August 21, 2023